CSIMarket Company Name, Ticker, Suppliers, else..
 
2seventy Bio Inc   (NASDAQ: TSVT)
Other Ticker:  
 
 
Price: $5.0000 $0.01 0.200%
Day's High: $5.01 Week Perf: 0.2 %
Day's Low: $ 4.99 30 Day Perf: 2.25 %
Volume (M): 1,158 52 Wk High: $ 5.30
Volume (M$): $ 5,791 52 Wk Avg: $4.07
Open: $5.00 52 Wk Low: $2.29



 Market Capitalization (Millions $) 267
 Shares Outstanding (Millions) 53
 Employees 202
 Revenues (TTM) (Millions $) 48
 Net Income (TTM) (Millions $) -4
 Cash Flow (TTM) (Millions $) 45
 Capital Exp. (TTM) (Millions $) 0

2seventy Bio Inc
2seventy Bio Inc is a biotechnology company that focuses on developing novel therapeutics for the treatment of various diseases. The company employs advanced genetic and protein engineering techniques to create innovative drug candidates. Their research and development efforts are primarily focused on oncology and rare diseases. 2seventy Bio Inc aims to provide targeted and effective treatments that address critical unmet medical needs.


   Company Address: 60 Binney Street Cambridge 2142 MA
   Company Phone Number: 675-7270   Stock Exchange / Ticker: NASDAQ TSVT


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
HOOK   -8.1%    
JNJ   -3.79%    
LLY   -3.33%    
MRK   -3.09%    
OGN   -1.89%    
SPRO        1.73% 
• View Complete Report
   



Business Update

s with its recent sale of the Hemophilia A gene therapy candidate and in vivo gene editing technology to Novo Nordisk...

Published Thu, Feb 6 2025 3:39 PM UTC

In a year marked by resilience and strategic refocusing, 2seventy bio, Inc. (Nasdaq: TSVT), has made significant strides in its efforts to establish a robust foothold within the biopharmaceutical industry. From achieving impressive sales results for its CAR-T therapy, Abecma, to the sale of its Hemophilia A candidate and gene editing technologies to Novo Nordisk, the company...
Announcement

A Comprehensive Examination of the Legal Inquiry into 2seventy bio, Inc. and Its Implications for the Biotechnology S...

Published Wed, Oct 9 2024 8:00 PM UTC

: The biotechnology sector continues to be a dynamic and volatile industry, characterized by rapid advancements in research and development juxtaposed against rigorous regulatory scrutiny and volatile market behaviors. A pertinent example of these fluctuations is evident in the recent investigation launched by the law firm Bronstein, Gewirtz & Grossman, LLC into potential se...
Announcement

Legal Inquiry into 2seventy bio, Inc. Bronstein, Gewirtz, and Grossman, LLC Calls Upon Investors for Assistance,

Published Fri, Sep 27 2024 8:00 PM UTC

CSIMarket.com : Edition September 27, 2024 Investigation Launched into 2seventy bio, Inc.: Investors Urged to Collaborate NEW YORK The renowned legal establishment of Bronstein, Gewirtz, and Grossman, LLC, hath declared an undertaking of an inquiry concerning potential grievances associated with the acquisitions of securities from 2seventy bio, Inc. (henceforth referred...
Business Update

2seventy bio Provides Update on KarMMa-9 Study and Previews Anticipated Strong Third Quarter Revenue Performance

Published Wed, Sep 25 2024 10:47 AM UTC

2seventy bio and Bristol Myers Squibb Discontinue Phase 3 KarMMa-9 Study Enrollment Amid Promising Q3 Financial Outlook CAMBRIDGE, Mass. - 2seventy bio, Inc. (Nasdaq: TSVT) recently announced a significant strategic development in collaboration with Bristol Myers Squibb (BMS). The two companies have decided to discontinue enrollment in the ongoing Phase 3 KarMMa-9 study, w...
Business Update

2seventy Bio Navigating Transformative Times Amidst Revenue Fluctuations

Published Wed, Aug 7 2024 11:51 AM UTC

In a compelling display of corporate metamorphosis, 2seventy bio, Inc. (NASDAQ: TSVT) has unveiled its financial results for Q2 2024, which depict a rollercoaster journey marked by both extraordinary growth and the specter of short-term challenges. The biopharmaceutical company, based in Cambridge, Massachusetts, signaled its significant transformation under CEO Chip Baird, ...






2seventy Bio Inc's Segments
Ide Cel Commercial Activities Bristol-Myers Squibb    79.07 % of total Revenue
ABECMA Commercial Activities    83.46 % of total Revenue
Bristol-Myers Squibb Outside of U S Ide-cel license and manufacturing services License and Manufacturing Services    16.45 % of total Revenue
Reportable Segment    100 % of total Revenue





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com